Osivax’ mission is to prevent globally impactful infectious diseases. Leveraging its unique oligoDOM® technology platform. The Company is developing a universal flu vaccine for both current and future influenza infections. OVX836 vaccine candidate is in Phase 2a clinical development.
Osivax is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. Osivax is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.
- Invested amount
EUR 3 930 975